Donnimab Advances in EU Review: New Hope, Limited Reach for Alzheimer’s Patients
A promising new treatment for Alzheimer’s disease, Donnimab, has received a positive recommendation for approval in the European Union, though its impact will be limited to a small percentage of those affected. The European Agency’s Medical Products Committee has advised granting a marketing license for the antibody therapy, designed to slow the progression of the disease in its early stages, but the European Commission now holds the final decision.
The recommendation marks a significant, albeit cautious, step forward in the fight against Alzheimer’s, a devastating condition impacting millions worldwide. While Donnimab cannot halt or reverse the disease, clinical trials suggest it can delay cognitive decline in select patients.
Global Approvals Pave the Way for European Consideration
Donnimab, marketed under the brand name Kissonla, has already secured regulatory approval in the United States, Japan, China, and Britain. This widespread international acceptance strengthens the case for its use within the EU. According to a company release, the drug’s approval in multiple major markets demonstrates its potential to address a critical unmet medical need.
However, the treatment’s efficacy is not universal. Estimates suggest that only approximately 10% of Alzheimer’s patients will be suitable candidates for Donnimab. In Germany alone, where 1.2 million people currently live with Alzheimer’s, this translates to roughly 120,000 individuals who might benefit.
A Second Antibody Treatment for Europe
If approved by the European Commission, Donnimab will become the second antibody treatment for Alzheimer’s available in the European Union. This growing arsenal of therapies offers a glimmer of hope for those in the early stages of the disease.
“The availability of multiple treatment options is crucial for personalized medicine,” a senior official stated. “Each patient responds differently, and having a range of therapies allows clinicians to tailor treatment plans to individual needs.”
The European Commission is expected to announce its decision regarding Donnimab’s approval in the coming months. The potential impact on the lives of those affected by Alzheimer’s, while limited in scope, represents a vital advancement in neurological care.
